Web15 jul. 2024 · The approval of nintedanib and pirfenidone for treatment of idiopathic pulmonary fibrosis has introduced complexity into the design of clinical trials for new … Web1 apr. 2024 · An earlier endpoint would enable assessment of a greater number of therapies in adaptive trial designs. Objectives:To determine whether short-term changes in FVC, DlCO, and six-minute-walk distance could act as surrogate endpoints to accelerate early-phase trials in IPF.
Patient considerations and drug selection in the treatment of ...
Web12 mrt. 2024 · IPF is a chronic, fibrotic, and progressive interstitial lung disease characterized by the histopathologic pattern of usual interstitial pneumonia in the absence of an identifiable cause or association. Disease progression is highly heterogeneous with a median survival of approximately 3–5 years following diagnosis. WebA decline in forced vital capacity (FVC) is indicative of disease progression in patients with IPF and change in FVC is the most commonly used endpoint in clinical trials [ 7, 8 ]. A decline in FVC of 5% or 10% of the predicted value over 6–12 months has been associated with increased mortality in patients with IPF [ 7, 9, 10 ]. eagle rare single barrel whiskey
Robert A. Tumasian III - LinkedIn
Web20 okt. 2024 · The purpose of this guidance is to describe various strategies for grouping and ordering endpoints for analysis and applying some well-recognized statistical … WebOptimal design and implementation of the appropriate prospective clinical trials are essential to demonstrate clinical efficacy of promising drugs for the treatment of IPF. A … WebTwo clinical trials, CAPACITY 004 and CAPACITY 006, were carried out to investigate the benefits of oral pirfenidone in IPF 17 across 110 centers in Australia, Europe, and North America. Patients were aged between 40 and 80 years, with measured FVC ≥50% predicted and diffusion capacity for carbon monoxide [DLco] ≥35%. eagle rare pa wine and spirits